Literature DB >> 22807512

The case for chemotherapy alone for limited-stage Hodgkin's lymphoma.

Joseph M Connors1.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22807512      PMCID： PMC3425518          DOI： 10.1634/theoncologist.2012-0228

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  7 in total

1.  ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.

Authors:  Ralph M Meyer; Mary K Gospodarowicz; Joseph M Connors; Robert G Pearcey; Woodrow A Wells; Jane N Winter; Sandra J Horning; A Rashid Dar; Chaim Shustik; Douglas A Stewart; Michael Crump; Marina S Djurfeldt; Bingshu E Chen; Lois E Shepherd
Journal:  N Engl J Med       Date:  2011-12-11       Impact factor: 91.245

2.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Authors:  Andreas Engert; Annette Plütschow; Hans Theodor Eich; Andreas Lohri; Bernd Dörken; Peter Borchmann; Bernhard Berger; Richard Greil; Kay C Willborn; Martin Wilhelm; Jürgen Debus; Michael J Eble; Martin Sökler; Antony Ho; Andreas Rank; Arnold Ganser; Lorenz Trümper; Carsten Bokemeyer; Hartmut Kirchner; Jörg Schubert; Zdenek Král; Michael Fuchs; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Volker Diehl
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

3.  The case for combined-modality therapy for limited-stage Hodgkin's disease.

Authors:  Christine E Hill-Kayser; John P Plastaras; Zelig Tochner; Eli Glatstein
Journal:  Oncologist       Date:  2012-07-17

4.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

5.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

Authors:  Christian Steidl; Tang Lee; Sohrab P Shah; Pedro Farinha; Guangming Han; Tarun Nayar; Allen Delaney; Steven J Jones; Javeed Iqbal; Dennis D Weisenburger; Martin A Bast; Andreas Rosenwald; Hans-Konrad Muller-Hermelink; Lisa M Rimsza; Elias Campo; Jan Delabie; Rita M Braziel; James R Cook; Ray R Tubbs; Elaine S Jaffe; Georg Lenz; Joseph M Connors; Louis M Staudt; Wing C Chan; Randy D Gascoyne
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

6.  Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

Authors:  David B Duggan; Gina R Petroni; Jeffrey L Johnson; John H Glick; Richard I Fisher; Joseph M Connors; George P Canellos; Bruce A Peterson
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

7.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.

Authors:  G Bonadonna; R Zucali; S Monfardini; M De Lena; C Uslenghi
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860
  7 in total
  1 in total

1.  Omitting or reducing radiotherapy in childhood or adolescence Hodgkin Lymphoma.

Authors:  Theodoros P Vassilakopoulos; Georgios Boutsikas; Vassilios Papadakis
Journal:  Transl Pediatr       Date:  2013-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.